Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 17;6:100145. doi: 10.1016/j.prdoa.2022.100145

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Authors. Published by Elsevier Ltd.

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Fig. 2 — Evaluation of (A) PTB by classification of levodopa responsiveness and (B) percent of individuals with bradykinesia from 09:00 to 18:00 by PTB grouping with evaluable morning data. Panel A shows the PTB of F, CNF, and UNF and subtypes of F (C_P C_WO, U_P, and U_WO). Percentages along the x-axis show their relative proportions. CNF: an individual whose bradykinesia was controlled (mBKS <26) at time of the first daily levodopa dose and remained controlled after the first dose. F: an individual whose bradykinesia was above target (mBKS ≥26) at time of the first daily levodopa dose and who experienced a significant levodopa response. UNF: an individual whose bradykinesia was above target at time of the first daily levodopa dose and remained above target after the first dose without evidence of a significant levodopa response. C_P: an individual whose bradykinesia is below target after the first daily levodopa dose and the bradykinesia persists below target for>2 h after the peak response. C_WO: an individual whose bradykinesia is below target after the first daily levodopa dose and subsequently experiences wearing “OFF.” U_P: an individual whose bradykinesia is above target after the first daily levodopa dose and persists. U_WO: an individual whose bradykinesia is above target after the first daily levodopa dose and who experiences a wearing “OFF” of the levodopa response they did experience. Panel B: Gray bars show the relative percentage of individuals with evaluable morning data experiencing bradykinesia from 09:00 to 18:00 in each PTB range, while green bars and maroon bars show the percentage with morning bradykinesia that is below or above target, respectively. Numbers may not sum to 100% due to rounding. CNF, controlled nonfluctuator; C_P, controlled persisting; C_WO, controlled wearing “OFF”; F, fluctuator; mBKS, median bradykinesia score; PTB, percent time in bradykinesia; UNF, uncontrolled nonfluctuator; U_P, uncontrolled persisting; U_WO, uncontrolled wearing “OFF.” (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)